Short answer
Editas Medicine, Inc. (EDIT) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $3M (down 39.2% year over year) with net income of −$25M.
Q1 2026 key financials · XBRL
- Revenue
- $3M
- −39.2% YoY
- Net income
- −$25M
- +67.2% YoY
- Operating margin
- -883.2%
- EPS (diluted)
- −$0.26
- +71.7% YoY
Source: XBRL data from the Editas Medicine, Inc. (EDIT) Q1 2026 10-Q on SEC EDGAR. USD.
Editas Medicine, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $2.8M, down 39% YoY from $4.7M, primarily reflecting deferred-revenue recognition in 2025
- Net loss $25.0M vs $76.1M YoY, with operating expenses $27.8M vs $80.8M
- Research and development expense $17.6M, down 34% YoY; restructuring charges $0 vs $40.9M
- Vertex 2026 annual license fee $10.0M received in first quarter
- EDIT-401 first-in-human trial planned later in 2026, with early proof-of-concept data expected by year-end
Risk Factors
- Patent-priority risk: PTAB reaffirmed Broad’s first-inventor status on March 26, 2026; CVC may appeal
- ToolGen interference risk: suspension lifted following the March 2026 PTAB decision, with proceeding duration uncertain
- Intellectual-property exclusivity risk: unsuccessful disputes could narrow, invalidate, or revoke licensed CRISPR patents
- European regulatory risk: European Patent Office opposition proceedings could revoke additional in-licensed patents
- Operational risk: loss of patent rights could require third-party licenses or halt product-candidate development, manufacturing, and commercialization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Editas Medicine, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.